
|Articles|May 26, 2021
Thoma Bravo to Acquire Greenphire
Advertisement
Thoma Bravo has announced that it has reached an agreement to acquire Greenphire from The Riverside Company. The deal, which is subject to customary regulatory approvals, is expected to close in the second quarter of this year. Jim Murphy, CEO of Greenphire, will continue to lead the company along with the existing management team in King of Prussia, PA.
Jefferies LLC and AGC Partners are serving as financial advisor to Greenphire and Jones Day is serving as legal counsel. William Blair is serving as financial advisor to Thoma Bravo and Kirkland & Ellis, LLP is serving as legal counsel.
Financial details were not disclosed.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps
5



